Lp(a) molar concentration predicts CVD, diabetes risk

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Andexanet alfa effectively reverses factor Xa inhibition

Publish date:: March 18, 2019

Key clinical point: Andexanet alfa significantly reduces anti–factor Xa activity.

Major finding: Approximately 82% of treated patients achieved good or excellent hemostasis.

Study details: A single-cohort study of 352 patients with acute major bleeding associated with factor Xa inhibition.

Disclosures: Portola Pharmaceuticals, the maker of andexanet alfa, funded the study.

Citation:

Milling TJ et al. ISC 2019, Abstract LB7.

This Week's Must Reads

Genetic test stratified AFib patients with low CHA2DS2-VASc scores,

Aspirin plus a DOAC may do more harm than good in some,

Colchicine pre-PCI improves biomarkers, not injury risk,

Health Care: More Uninsured As Insurance Costs Grow Faster,

Intensive BP control reduced dementia but increased brain atrophy and hurt cognition,

Must Reads in Stroke

Aspirin plus a DOAC may do more harm than good in some,

Large Population-Based Study Underscores Link Between Gout, CVD Event Risk,

Minimize blood pressure peaks, variability after stroke reperfusion,

Pediatric stroke thrombectomy study sheds light on off-label procedure,

Early Infusion of Mononuclear Cells May Benefit Stroke Patients,

Menu Close